Detailed INTerpath-001 data confirm Moderna, Merck cancer vaccine met key endpoints in melanoma trial

Moderna and Merck's personalized cancer vaccine met key endpoints in a melanoma trial, with detailed data now confirming the result.

Detected & updated continuously · Source: Nebula